研究单位：[1]Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology Wuhan,Hu Bei,China,430000
研究目的：
This study is a single-center, open Phase I study, to observe the effectiveness and safety of CT103A combined with different doses of Selinexor in patients with relapsed/refractory extramedullary multiple myeloma, and the pharmacokinetics of Selinexor and CT103A Kinetic and pharmacodynamic characteristics.
